# UroMems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/uromems

- Industry: Medical Devices & Equipment
- Headquarters: Grenoble, France
- Website: www.uromems.com/
- Total disclosed funding: $75M
- Latest round: Series C (Jun 25, 2024)
- Investors on record: 11

## About

Based in France, SAS UroMems specializes in advanced medical devices focused on treating severe stress urinary incontinence (SUI) through innovative implantable technology. SAS UroMems, founded in 2011 in Grenoble, France, develops medical technology aimed at addressing urinary incontinence. The co-founders, Hamid LAMRAOUI (CEO), Pierre Mozer and Stephane Lavallee, have established the company as a significant player in the field. In May 2026, SAS UroMems raised USD 60 million in venture funding from ICONIQ Capital. UroMems focuses on developing advanced medical technologies, specifically its flagship product, UroActive™, which addresses severe stress urinary incontinence (SUI) for both genders. The implantable device is engineered to adapt automatically to individual patient needs, enhancing their quality of life. Currently in clinical investigations, UroActive™ aims to enter broader markets upon successful evaluation and regulatory approval, collaborating closely with urologists and healthcare providers in North America and Europe.In 2020, UroMems reported revenue of USD 0.00, indicating a focus on product development rather than sales at this stage. The company’s revenue model relies on partnerships with healthcare providers and clinical institutions, where revenues are expected to arise from UroActive™ sales as they progress through clinical stages and reach commercialization. The company plans to utilize the May 2026 funding to conduct key clinical trials for its implant technology and collect the necessary data for regulatory approval in several countries.

## Funding rounds

- Series C, Jun 25, 2024, $47M — Wellington Partners, Credit Mutuel Equity, b2venture, Bpifrance Investissement, Supernova Invest, Montpensier Arbevel, European Innovation Council, Hil-Invent GmbH
- Series B, Apr 6, 2021, $8.3M — Wellington Partners, Bpifrance, b2venture, Supernova Invest, Montpensier Arbevel, Hil-Invent GmbH
- Series B, May 20, 2020, $14M — Wellington Partners, b2venture, CITA Investissement, Bpifrance Investissement, Supernova Invest, Montpensier Arbevel, Hil-Invent GmbH
- Series A, Nov 15, 2016, $6M — Wellington Partners, CEA Investissement, b2venture, CITA Investissement, Bpifrance Investissement

## Investors

- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series A, Series B, Series C
- CEA Investissement (https://capitalatlas.ai/funds/cea-investissement) — Series A
- b2venture (https://capitalatlas.ai/funds/b2venture) — Series A, Series B, Series C
- CITA Investissement (https://capitalatlas.ai/funds/cita-investissement) — Series A, Series B
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A, Series B, Series C
- Supernova Invest (https://capitalatlas.ai/funds/supernova-invest) — Series B, Series C
- Montpensier Arbevel (https://capitalatlas.ai/funds/montpensier-arbevel) — Series B, Series C
- Hil-Invent GmbH — Series B, Series C
- Bpifrance — Series B
- Credit Mutuel Equity (https://capitalatlas.ai/funds/credit-mutuel-equity) — Series C
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series C